Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
01. November 2023 08:00 ET
|
Ocular Therapeutix, Inc.
The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a...
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
24. Oktober 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
03. Oktober 2023 16:01 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative...
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
06. September 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
09. August 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
07. August 2023 16:01 ET
|
Ocular Therapeutix, Inc.
DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted...
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
24. Juli 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces Appointment of New Board Member
12. Juli 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
10. Juni 2023 18:30 ET
|
Ocular Therapeutix, Inc.
OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic...
Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
07. Juni 2023 08:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative...